心脏病患者的抑郁症：需要更多试验的理由。
Depression in patients with heart disease: the case for more trials.
作者信息
Liu Stanley S, Ziegelstein Roy C
机构信息
Johns Hopkins Bayview Medical Center, Department of Medicine, B-1-North, 4940 Eastern Avenue, Baltimore, MD 21224-2780, USA.
出版信息
Future Cardiol. 2010 Jul;6(4):547-56. doi: 10.2217/fca.10.18.
Depression is common among patients with heart disease. It is an important comorbidity, both because of its well-known effect on the quality of life and also because it has a significant impact on the ability of patients with heart disease to engage in healthy behaviors and to avoid unhealthy ones. In addition, depression is associated with increased morbidity and mortality in those with established cardiovascular disease. However, no study has demonstrated that treatment of depression improves cardiac outcomes in patients with heart disease. Some have argued that additional trials are not necessary, and that the importance of depression argues for increased recognition and treatment even if it cannot be demonstrated that this improves morbidity and mortality. This article makes the case for more trials in this area, highlighting the importance of using the results of prior trials to generate hypotheses and provide directions for future studies in this area and noting the effect that demonstrating improved survival might have on clinical practice.
抑郁症在心脏病患者中很常见。它是一种重要的合并症，这既是因为其对生活质量的众所周知的影响，也是因为它对心脏病患者参与健康行为和避免不健康行为的能力有重大影响。此外，抑郁症与已确诊心血管疾病患者的发病率和死亡率增加有关。然而，尚无研究表明治疗抑郁症能改善心脏病患者的心脏预后。一些人认为没有必要进行更多试验，并且抑郁症的重要性表明即使无法证明这能改善发病率和死亡率，也应提高对其的认识和治疗。本文主张在该领域进行更多试验，强调利用先前试验结果来生成假设并为该领域未来研究提供方向的重要性，并指出证明生存率提高可能对临床实践产生的影响。
Zotero 插件